
Opinion|Videos|August 5, 2024
Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC
The panel of experts in lung cancer examines genetic alterations affecting treatment response and biomarker testing rates in metastatic non-small cell lung cancer (mNSCLC).
Advertisement
Video content above is prompted by the following:
- How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance?
- In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement